Compare RNW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | VERA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United Kingdom | United States |
| Employees | 4336 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 3.2B |
| IPO Year | N/A | 2021 |
| Metric | RNW | VERA |
|---|---|---|
| Price | $5.96 | $33.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $81.30 |
| AVG Volume (30 Days) | 935.6K | ★ 969.5K |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | $472.48 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $18.76 |
| 52 Week High | $8.24 | $56.05 |
| Indicator | RNW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 39.09 |
| Support Level | $5.20 | $34.04 |
| Resistance Level | $7.80 | $42.77 |
| Average True Range (ATR) | 0.24 | 1.94 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 91.56 | 17.80 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.